126 results about "Pyroptosis" patented technology

The invention relates to an astragaloside-loaded astragalus membranaceus exosome which is prepared by the following steps: crushing astragalus membranaceus, and filtering to obtain juice; performing multi-step differential centrifugation to obtain supernate; carrying out ultrafiltration and centrifugation, and collecting the precipitate; adding to the upper layer of a sucrose stepped gradient solution, centrifuging, and collecting part of strips; after dilution, centrifuging, discarding the supernatant, precipitating, and removing cane sugar to obtain the astragalus membranaceus exosome; the radix astragali exosome loaded with the astragaloside is obtained by mixing the radix astragali exosome with the astragaloside and carrying out ultrasonic treatment or co-incubation, and can be used for preparing medicines for specifically inhibiting cGAS / STING pathway excessive activation in cerebral ischemia reperfusion injury and downstream NLRP3 inflammasome mediated pyroptosis and preparing medicines for protecting and repairing mitochondria in the cerebral ischemia reperfusion injury. The homologous astragalus membranaceus exosome is used as a natural carrier, the blood-brain barrier is effectively overcome, and the enrichment concentration and bioavailability of astragaloside in a cerebral ischemia area are remarkably improved.

The invention discloses a composition for enhancing cold resistance based on pyroptosis regulation and a preparation method thereof, and belongs to the technical field of biological medicines. The preparation method of the composition for enhancing cold resistance based on pyroptosis regulation comprises the following steps: S1, respectively preparing an angelica sinensis aqueous extract and an astragalus membranaceus aqueous extract; and S2, mixing the angelica sinensis aqueous extract and the astragalus membranaceus aqueous extract according to the mass ratio of 1: (4-20) to obtain the composition for enhancing cold resistance based on pyroptosis regulation. The invention further provides a composition obtained based on the preparation method, a preparation and application. The composition provided by the invention can significantly prolong the survival time of acute cold exposure mice; the core body temperature of an acute cold exposure mouse is obviously improved, liver injury is relieved, and liver tissue cell pyroptosis pathway protein expression is regulated.

The application provides a group of small interfering RNAs (siRNAs) targeting pyroptosis-related inflammatory reaction genes and application thereof. The pyroptosis-related inflammatory reaction genes include IL1A, IL1B, IL6, HMGB1, S100A8, S100A9 and BACH1. The application designs and synthesizes specific siRNA sequences for the above genes, and verifies that the siRNAs can efficiently and specifically inhibit the mRNA expression level of the corresponding genes through cell transfection and real-time fluorescent quantitative PCR. The application also provides a composition containing the siRNAs, a pharmaceutical composition and application thereof in the preparation of a drug for treating diseases mediated by pyroptosis-related inflammatory reaction genes (especially inflammatory diseases). The siRNAs and the composition thereof provide a new effective strategy for treating diseases related to excessive activation of pyroptosis-related inflammatory reactions, and have a wide application prospect.

The disclosure belongs to the technical field of medicine. Provided are a CD97 and GSDME interaction inhibitor having anti-tumor activity and an application thereof. A compound screened in the disclosure enhances the susceptibility of NK cells to kill tumor cells by inhibiting the interaction between GSDME and CD97 in tumor cells, so as to induce an immune anti-tumor effect. Moreover, the compound enhances the susceptibility of tumor cells to pyroptosis by blocking the protective effect of CD97 on cleavage of GSDME proteins. Therefore, the compound can be used for treating GSDME and CD97 double-positive malignant tumors, and combined chemotherapy, immunotherapy, etc., to enhance the susceptibility of malignant tumors to chemotherapy and immunotherapy, prolonging the overall survival period of patients with malignant tumors. Specifically provided is a compound having a structure set forth in formula (I), a pharmaceutically acceptable salt, a solvent compound or a deuterated compound thereof.

The application relates to the field of biological medicine, and particularly discloses application of a sophora japonica extract in preparation of a product for improving the reproductive performance of ewes. The sophora japonica extract can effectively inhibit pyroptosis of ovarian granulosa cells by down-regulating expression of cysteine protease B, further reverses follicle atresia and ovulation disorders caused by pyroptosis, and improves the reproductive performance; animal experiments show that the sophora japonica extract can optimize the follicle development structure of ewes, inhibit overdevelopment of large follicles, and significantly improve the ovulation efficiency, thereby providing a new scheme for inhibiting pyroptosis of ovarian granulosa cells and improving the reproductive performance of livestock.

The invention discloses a marsdenia tenacissima extract as well as a preparation method and application thereof, and belongs to the technical field of medicines. The marsdenia tenacissima extract is Marsdenside A or Marsdenside C, and the structural formulas of the marsdenside A and the Marsdenside C are respectively shown as a formula I and a formula II. Marsdenside C can induce ferroptosis and inhibit liver cancer, and the liver cancer is liver cancer caused by HepG2 or Huh7 cells; the Marsdenside A induces pyroptosis to play a role in inhibiting the gastric cancer, and the gastric cancer is caused by HGC-27 or AGS cells, so that the Marsdenside C can be used for preparing the medicine for resisting the liver cancer, and the Marsdenside A can be used for preparing the medicine for resisting the gastric cancer.

The invention relates to an application of an MYOF protein in preparation of a product for preventing, relieving and / or treating acute lung injury. According to the application, the MYOF protein can be combined with GSDMD-NT, and up-regulation of expression of the MYOF protein can effectively inhibit activation of GSDMD and pyroptosis mediated by GSDMD, so that the MYOF protein has an application prospect in preparation of products for preventing, relieving and / or treating acute lung injury, and the technical problem that alveolar epithelial barriers are easily damaged during treatment can be solved.

The invention provides a method for treating autoimmune diseases mediated by regulatory T cell (Treg) programmed necrosis. Specifically, the invention provides application of an O-linked beta-N-acetylglucosamine glycosylation (O-GlcNAcylation) accelerant, and the O-linked beta-N-acetylglucosamine glycosylation accelerant is used for preparing a medicine or a preparation for treating programmed necrosis type autoimmune diseases. It is found for the first time that when the O-GlcNAcylation promoter is used for improving the O-GlcNAcylation level of RIPK1 / 3 protein, Treg programmed necrosis can be effectively inhibited, and therefore autoimmune diseases are improved.

This invention discloses the application of American ginseng glycoprotein extract in the preparation of drugs for treating alcoholic liver disease, belonging to the field of biomedical technology. This invention verifies that TD can significantly reduce serum ALT, AST, and TG levels in ALD mice, effectively reducing liver damage and lipid accumulation; inhibit NLRP3 protein expression and its downstream targets, effectively alleviating liver inflammation and pyroptosis; and improve intestinal flora imbalance in ALD mice. American ginseng glycoprotein extract has multi-target protective effects against alcoholic liver disease, reducing alcohol-induced liver tissue inflammation and oxidative stress damage. It has a mild composition and high safety profile, and can synergistically exert effects in liver protection, anti-inflammation, and antioxidation, making it suitable for adjunctive intervention and long-term management of alcoholic liver disease, providing a natural, mild, and effective protective pathway for alcoholic liver damage.

The present application belongs to the technical field of coordination chemistry and biomedical science, and provides a multifunctional iridium (III) complex, a preparation method and application thereof. The multifunctional iridium (III) complex (Mito-Ir) is composed of an iridium (III) complex cation and a coordination anion shown in the following formula. Mito-Ir can efficiently target mitochondria, and also has the abilities of phosphorescence imaging, type I and type II active oxygen generation, and photocatalytic oxidation of nicotinamide adenine dinucleotide. Under light irradiation, Mito-Ir triggers severe mitochondrial dysfunction through the above synergistic effect, and then specifically activates the caspase-3 / GSDME signaling pathway, and significantly induces pyroptosis; this pyroptosis-based cell death mechanism can effectively overcome the apoptosis tolerance of tumor cells, and is accompanied by the release of a large amount of inflammatory factors and damage-associated molecular patterns, stimulates immunogenic cell death, and activates the body's anti-tumor immune response.

The invention relates to a caspase-1 responsive fluorescent probe based on FRET (Fluorescence Resonance Energy Transfer), a preparation method, application and a product, and belongs to the technical field of FRET fluorescent probes. The technical problem to be solved is to provide the FRET fluorescent probe capable of simultaneously carrying out in-vitro caspase-1 enzyme detection and in-vivo caspase-1 activity detection, and the specific technical scheme is that the FRET fluorescent probe with a chemical structure shown in a formula I is provided. The FRET fluorescent probe provided by the invention has short reaction time, is suitable for caspase-1 activity detection and pyroptosis imaging under a fluorescence confocal microscope, and can realize multi-scale imaging of pyroptosis in cell spheres and animal bodies.

The invention relates to a preparation method of a heavy-atom-free photosensitizer based on a BODIPY dye, the photosensitizer comprises a thiocarbamate light cage, not only can generate singlet oxygen (1O2) under red light irradiation, but also can release carbonyl sulfide (COS), and generates hydrogen sulfide (H2S) under physiological conditions through carbonic anhydrase catalysis. By reasonably adjusting the molecular structure, the singlet oxygen quantum yield and hydrogen sulfide release efficiency of the photosensitizer are remarkably improved. The method is the first case which is reported at present and can simultaneously activate and release the organic optical functional micromolecules of H2S and 1O2 through a single beam of red light. The strategy effectively solves the problem of dependence on oxygen in type II photodynamic therapy (PDT), and further effectively improves the effect of PDT hypoxic tumors. In in-vitro and in-vivo experiments, hydrogen sulfide gas and photodynamic synergic treatment trigger pyroptosis of cells, promote maturation of dendritic cells and stimulate antitumor immune response. Therefore, the invention provides a synergistic treatment strategy combining gas, photodynamic and immunotherapy, and has a remarkable effect in the aspect of hypoxic tumor treatment. The photosensitizer material disclosed by the invention is simple to prepare and low in cost, has a wide application prospect, and particularly provides a solution with huge potential for cancer treatment in the field of biomedicine.

The invention provides saCNTF-DSF-LNP composite nanoparticles as well as a preparation method and application of the saCNTF-DSF-LNP composite nanoparticles, and particularly relates to application of the saCNTF-DSF-LNP to preparation of medicines for treating diseases related to optic nerve injury. The method comprises the following steps: S1, preparing self-amplification CNTF RNA, and naming the self-amplification CNTF RNA as saCNTF; s2, preparing lipid nano particles entrapped with the disulfiram DSF; s3, quickly adding the ethanol phase containing the disulfiram DSF-lipid mixture into the aqueous phase containing the saCNTF, and mixing, so that the nanoparticles are formed by self-assembly; s4, purifying the nano particles by using an ultrafiltration centrifugal device to obtain saCNTF-DSF-LNP; the invention provides a preparation method and application of saCNTF-DSF-LNP, the saCNTF-DSF-LNP can inhibit neuroinflammation driven by acute pyroptosis, and continuous neurotrophic support is provided for RGC survival and long-term axon regeneration; according to saCNTF-DSF-LNP, continuous expression of CNTF is achieved through saRNA, efficient targeted delivery is achieved by means of LNP so as to reduce off-target toxicity of DSF, and a new treatment strategy is provided for neuritis and degenerative diseases.

The invention provides an application of OICR-9429 or a pharmaceutically acceptable salt thereof in preparation of a product for improving senescence indications. The OICR-9429 provided by the invention shows multiple beneficial technical effects in the aspect of improving senescence-related indications, not only can effectively relieve inflammatory response caused by pyroptosis in the senescence process, but also can improve the immune function and anti-infection ability of senescence organisms. The OICR-9429 also has a remarkable treatment effect on sepsis, the increase of the inflammation level caused by infection is inhibited, the survival rate of old patients is increased, and the prognosis is improved. Long-term intervention of the OICR-9429 can continuously relieve the chronic inflammation state of an aging body, increase the muscle mass, enhance the exercise ability, prolong the life and reduce various lesions accompanied by aging. The invention lays a foundation for developing products for comprehensively intervening aging and related function decline, and has important application value in the aspect of improving the life quality of old people.

This invention discloses a small-molecule pyroptosis inducer for tumor cells. It utilizes an N,N-diethylimine group as an electron acceptor (A), a rhodamine scaffold as a π-conjugated system, thiophene and triphenylamine groups as the first electron donor (D1) and second electron donor (D2), respectively, and a rotatable vinyl and C-C single bond to increase intramolecular motion, forming a novel A-π-D1-D2 type small-molecule pyroptosis inducer, Rd-TTPA, with enhanced D-A structure and intramolecular motion. This small-molecule pyroptosis inducer can efficiently target tumor cell mitochondria, inducing pyroptosis through ultrasound-mediated reactive oxygen species production. It can serve as an enhanced sonodynamic deep tumor therapeutic agent guided by near-infrared II (NIR-II) fluorescence imaging.

The invention belongs to the technical field of biological medicines, and particularly relates to a membrane-coated oncolytic virus as well as a preparation method and application thereof. The oncolytic virus contains a GSDMD N-terminal expression cassette regulated and controlled by a heated shock promoter, and pyroptosis can be induced under exogenous mild thermal stimulation, so that the virus is promoted to be quickly released, and reinfection and amplification of adjacent tumor cells are realized. A bionic nano-vesicle (iNV) formed by a donor cell membrane modified by genetic engineering is used as an outer layer to coat a genetically engineered oncolytic virus (GOV) to obtain a membrane-coated oncolytic virus iNV-GOV, so that the membrane-coated oncolytic virus iNV-GOV simultaneously has immunocompatibility and active tumor recognition capability, is suitable for solid tumors such as pancreatic ductal adenocarcinoma (PDAC), hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (IHCC) and the like, and can be used for preparing an anti-tumor drug. And the tumor volume can be obviously reduced in mouse in-vivo model experiments.

The invention belongs to the field of tumor nano immunotherapy, and particularly relates to a nano immunotherapeutic agent cooperating with I / II type photodynamic and multiple cell death and anti-tumor application of the nano immunotherapeutic agent. The invention successfully constructs the nanoparticles (HMB) capable of targeting mitochondria and simultaneously exciting the photodynamic effects of the type I and the type II. Based on in-vitro and in-vivo experiments of a system, it is verified that ferroptosis and pyroptosis can be effectively triggered through photodynamic therapy mediated by the combination of the HMB and a ferroptosis inducer sulfasalazine. The multi-mode cell death network constructed by combining HMB with salazosulfapyridine represents a novel promising cancer treatment method, so that a novel strategy with transformation potential is provided for solid tumor treatment; and an important theoretical and practical basis is provided for deeply understanding a tumor cell death mechanism and designing a new-generation intelligent photosensitizer system according to the death mechanism.

The invention discloses screening of transcriptome biomarkers responsive to tanshinone IIA and application of the transcriptome biomarkers in sepsis diagnosis and treatment kits. Tanshinone IIA (TSA) inhibits an SAMSN1 gene in a targeted manner by up-regulating expression of mmu-miR-1896, so that an NRF2 / KEAP1 antioxidant pathway is activated, and GSDMD-mediated pyroptosis is inhibited, thereby reducing multi-organ injury. 10-20 mg / kg of TSA can significantly improve the alveolar structure of the LPS model and reduce inflammatory factors. A kit which is developed on the basis of the mechanism and is used for detecting the expression levels of mmu-miR-1896, SAMSN1 and NRF2-Kea1-GSDMD can be used for evaluating the curative effect.

This invention discloses a glycyrrhizic acid nanomedicine, its preparation method, and its applications, belonging to the field of biomedical nanomaterials technology. The glycyrrhizic acid nanomedicine is prepared by reacting ammonium glycyrrhizate and sodium oleate at a temperature of 15-40 °C. o Glycyrrhizate nanomedicine was prepared via a microemulsion method at temperature C. After entering tumor cells, the glycyrrhizate nanomedicine was rapidly degraded within the acidic lysosomes of the tumor cells, releasing a large amount of sodium. + The presence of glycyrrhizic acid ions and glycyrrhizic acid ions causes a surge in intracellular ion concentration and osmotic pressure, as well as the accumulation of glycyrrhizic acid within tumor cells. This induces pyroptosis in tumor cells and regulates the expression of proliferation-related proteins. Pyroptosis releases a large number of damage-associated molecular patterns (DAMPs) to trigger immune activation, while the regulation of proliferation-related protein expression inhibits tumor cell proliferation. Under the combined effect of these two factors, glycyrrhizic acid nanomedicines can not only activate the systemic anti-tumor immune response but also reduce tumor cell spread, thereby effectively inhibiting tumor growth and metastasis and enhancing the efficacy of tumor immunotherapy.

The invention relates to the field of aggregation-induced emission photosensitizers, in particular to a mitochondria-targeted aggregation-induced emission photosensitizer as well as a preparation method and application thereof. The aggregation-induced emission photosensitizer disclosed by the invention is simple in synthetic route, is emitted in a near-infrared region, has deeper tissue penetration depth and excellent photodynamic activity, realizes specific killing of tumor cells through precise targeting mitochondria, triggers pyroptosis of cells and regulates and controls whole-body anti-tumor immune response.

The construction and application of an intratumorally self-proliferating enhanced oncolytic microbial delivery system belongs to the field of pharmaceutical formulation technology. Through a synthetic reaction, a hydrogen sulfide donor is endowed with a membrane-intercalable regional structure. Then, a lipid membrane containing the membrane-intercalable hydrogen sulfide donor is used to encapsulate bacteria through self-assembly, thus preparing an intratumorally self-proliferating enhanced oncolytic microbial delivery system. After intravenous injection of the delivery system, it accumulates within the tumor. In the tumor inflammatory microenvironment, the hydrogen sulfide released by the donor can be converted into tetrathionate. Tetrathionate respiration is a unique form of respiration in Salmonella. Through both aerobic and tetrathionate respiration, the system specifically promotes the proliferation of Salmonella in the tumor site, thereby enhancing tumor cell pyroptosis and achieving anti-tumor effects. This invention provides a novel theory and advanced solution for cancer treatment, and also offers promising strategies and exploratory ideas for the clinical application of attenuated Salmonella, possessing significant scientific research value.

This invention relates to the fields of pharmaceuticals and nanomedicine, specifically disclosing the preparation of a dual-targeting liposome drug delivery system and its application in stroke. The dual-targeting liposome drug delivery system comprises neutrophils, artemisinin, edaravone, and liposomes. The liposomes co-load artemisinin and edaravone, and their surfaces are modified with sialic acid derivatives and phosphatidylserine to form liposome nanomedicines. The neutrophils act as carriers, transporting the drug across the brain border (BBB) ​​and targeting it to the ischemic brain region. This dual-targeting strategy achieves precise two-stage drug delivery to the ischemic brain region. This delivery system can inhibit NLRP3 inflammasome activation, reduce pyroptosis, and promote microglial polarization towards the M2 anti-inflammatory phenotype, thereby effectively treating cerebral ischemia-reperfusion injury or ischemic stroke.

The invention provides application of EMD638683 and a compound thereof as a therapeutic target to preparation of a medicine for treating gastric cancer, relates to the technical field of biomedicine, and is technically characterized by providing application of EMD638683 (R-Form) as a therapeutic target to preparation of a medicine for treating gastric cancer. According to the application, a specific verification test proves that EMD638683 (R-Form) is targeted to an N40 glycosylation site of LT beta R, a TRIM28 / PCBP2 / SARM1 pathway is specifically blocked, and the off-target toxicity is low. After the cRGD modified liposome is delivered, the tumor specific enrichment can be realized, the bioavailability is improved, the damage to normal organs is reduced, and the safety is good. The medicine can effectively reverse gastric cancer radiotherapy resistance, is adaptive to radiotherapy non-responders with high LT betaR expression, assists in precise stratified treatment, and improves the survival rate of patients. A traditional DNA repair related mechanism is broken through, the sensitization effect is achieved by regulating and controlling a pyroptosis pathway, and a brand new direction is provided for research and development of gastric cancer radiotherapy sensitization drugs.

The present application relates to the field of biological medicine, in particular to a tumor treatment platform based on endogenous and exogenous zinc overload strategy, a preparation method and application. For the treatment platform, it comprises an acid-sensitive carrier, zinc ions and a sound-sensitive organic ligand; the sound-sensitive organic ligand can generate reactive oxygen under ultrasonic irradiation; the sound-sensitive organic ligand and the zinc ions are connected by a coordination bond to form a metal-organic complex; and the metal-organic complex is loaded on the acid-sensitive carrier. The present application proposes a tumor treatment strategy of "endogenous-exogenous synergy", combines "exogenous Zn 2+ " delivery with "endogenous Zn 2+ " mobilization, successfully induces "Zn 2+ overload" in cells through the synergistic effect of the two, realizes the precise, efficient and controllable induction of local Zn 2+ overload in tumors, and improves the effectiveness of pyroptosis. Through the present application, the limitations of traditional methods in controllability, efficacy and safety are overcome.

This invention relates to an immune-enhancing polypeptide and its applications, specifically providing an immune-enhancing polypeptide, wherein the polypeptide is the N-terminal amino acid sequence of pyroptosis-associated protein GSDMD from position 1 to 500 or a truncated sequence thereof. The immune-enhancing polypeptide described herein can induce a stronger immune response and can simultaneously satisfy multiple antigen loading formats.

Disclosed are an aggregation-induced emission photosensitizer and a pharmaceutical composition constructed therefrom, a preparation method therefor and the use thereof. The aggregation-induced emission photosensitizer MTCN-3 has a great reactive oxygen species generation capacity and a photothermal effect, thus exerting the dual effect of inducing pyroptosis and ferroptosis in tumor cells. The aggregation-induced emission photosensitizer is also capable of exerting a synergistic photoimmunotherapeutic effect with an immune agonist Poly(I:C). A co-assembled pharmaceutical composition has a near-infrared aggregation-induced emission effect, exhibits good subcellular distribution, and has active targeting selectivity for tumor cells. The pharmaceutical composition eliminates tumors and prevents tumor metastasis by means of inhibiting immune evasion, and inhibits the growth of both primary and distal tumors, thereby exerting a systemic anti-tumor immune effect. The pharmaceutical composition exhibits high stability and low toxic side effects, and has broad prospects for clinical application.

The invention discloses application of berberine in preparation of a medicine for treating non-small cell lung cancer, and belongs to the technical field of biological medicine. The invention provides an application of berberine in preparation of a medicine for inhibiting or treating EGFR (epidermal growth factor receptor) driven diseases, or an application of berberine combined with other medicines in preparation of a medicine for inhibiting or treating EGFR driven diseases. The diseases comprise non-small cell lung cancer driven by EGFR (epidermal growth factor receptor). It is found that in PC-9 cells, berberine induces ROS accumulation and starts a mitochondrial injury pathway, then mitochondrial membrane potential is reduced, GSDME is activated to form an active N-terminal fragment (GSDME-N), then pyroptosis is induced, NSCLC cell proliferation is inhibited, and berberine is expected to overcome or delay EGFR TKI drug resistance and improve clinical effects and survival prognosis.

The invention relates to medical application of IRF9 in prevention and treatment of trastuzumab (TRZ) cardiotoxicity, and belongs to the technical field of biological medicine. The invention reveals that the expression of the interferon regulatory factor 9 (IRF9) in the TRZ cardiotoxic myocardial tissue is up-regulated for the first time, and myocardial damage is aggravated by promoting pyroptosis of myocardial cells. On the basis, the invention provides the IRF9 as a diagnostic marker of TRZ cardiotoxicity, and provides an application of an IRF9 low expression vector or small interfering RNA (siRNA) in preparation of drugs for preventing or treating TRZ cardiotoxicity. Animal experiments show that cardiac function decline, cardiac hypertrophy and fibrosis caused by TRZ can be remarkably improved by myocardial cell specific low-expression IRF9. The invention provides a new target spot and an intervention strategy for clinical prevention and treatment of TRZ cardiotoxicity.

The present application relates to the field of biological medicine nanomaterials, and particularly relates to a kind of nanocomposite material and its preparation method and application.The preparation method of nanocomposite material provided by the present application, first, by a kind of room temperature fast, green method is synthesized hollow sodium bismuth fluoride carrier, and doping makes it have excellent upconversion luminescence performance, then using the excellent surface area of hollow sodium bismuth fluoride is successfully loaded photosensitizer MC540, clothing mould toxin, finally using DSPE-PEG-FA is modified, obtains nanocomposite material.It can effectively activate tumor cell endogenous calcium overload, induce tumor cell pyroptosis, realize the effect of efficient cancer treatment.

The invention discloses a recombinant plasmid for expressing recombinant pyroptosis protein, an engineering strain, a preparation method of the engineering strain and a tumor vaccine. The recombinant plasmid comprises an expression vector and a coding sequence which is inserted into the expression vector and is used for coding pyroptosis protein, the expression vector comprises pCDFDuet and pExoS54F, and the expression vector comprises pCDFDuet and pExoS54F; the coding sequence is added with a connection switch disulfide bond linker responding to glutathione in a tumor microenvironment. The recombinant plasmid constructed by the invention can be delivered through bacteria with tumor targeting, can stably express tumor microenvironment response recombinant pyroptosis protein, reduces damage to normal cells, and is a safe and efficient protein drug delivery technology.